Faiz Khan, MD
Family Medicine · la Porte, INNPI 1861698904
Payments from drug & device makers
Across 155 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$432
- AbbVie$321
- Pfizer$208
- Novartis$202
- GSK$159
- Boehringer Ingelheim$150
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,848100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $432 |
| AbbVie(2 entities) | 18 | $321 |
| Pfizer | 13 | $208 |
| Novartis | 16 | $202 |
| GSK | 11 | $159 |
| Boehringer Ingelheim | 8 | $150 |
| Boston Scientific | 3 | $146 |
| AstraZeneca | 2 | $139 |
| Lilly USA, LLC | 5 | $110 |
| Shield Therapeutics Inc | 1 | $104 |
| Vanda Pharmaceuticals Inc. | 2 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Amgen | 4 | $57 |
| Exact Sciences | 3 | $56 |
| Merck | 4 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Lundbeck LLC | 2 | $45 |
| Johnson & Johnson | 2 | $39 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Bayer | 2 | $36 |
| Dexcom, Inc. | 2 | $28 |
| Intuitive Surgical | 1 | $26 |
| Alkermes, Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,848 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $101,085 |
| OzempicSemaglutide | 61 | $89,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $85,269 |
| EliquisApixaban | 99 | $78,022 |
| JanuviaSitagliptin Phosphate | 100 | $66,086 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $40,021 |
| FarxigaDapagliflozin Propanediol | 33 | $39,971 |
| XareltoRivaroxaban | 15 | $24,868 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $24,028 |
| MounjaroTirzepatide | 20 | $19,347 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $17,326 |
| Spiriva RespimatTiotropium Bromide | 30 | $17,179 |
| LinzessLinaclotide | 23 | $15,927 |
| TrulicityDulaglutide | 15 | $13,843 |
| TradjentaLinagliptin | 18 | $12,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $159 | $149,318187 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $150 | $130,998114 claims |
| Novo NordiskOzempic | $432 | $89,19761 claims |
| PfizerEliquis | $208 | $78,02299 claims |
| MerckJanuvia | $56 | $66,086100 claims |
| AstraZenecaFarxiga, Symbicort | $139 | $46,31555 claims |
| Lilly USA, LLCMounjaro, Trulicity | $110 | $33,19035 claims |
| Johnson & JohnsonXarelto | $39 | $24,86815 claims |
| AbbVieLinzess, Synthroid | $321 | $18,41064 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in la Porte
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.